Abstract:Augmenting randomized controlled trials (RCTs) with external real-world data (RWD) has the potential to improve the finite sample efficiency of treatment effect estimators. We describe using adaptive targeted maximum likelihood estimation (A-TMLE) for estimating the average treatment effect (ATE) by decomposing the ATE estimand into two components: a pooled-ATE estimand that combines data from both the RCT and external sources, and a bias estimand that captures the conditional effect of RCT enrollment on the outcome. This approach views the RCT data as the reference and corrects for inconsistencies of any kind between the RCT and the external data source. Given the growing abundance of external RWD from modern electronic health records, determining the optimal strategy to select candidate external patients for data integration remains an open yet critical problem. In this work, we begin by studying the robustness property of the A-TMLE estimator and then propose a matching-based sampling strategy that attempts to improve the robustness of the estimator with respect to the target estimand. Our proposed strategy is outcome-blind and involves matching based on two one-dimensional scores: the trial enrollment score and the propensity score in the external data. We demonstrate in simulations that our sampling strategy improves the coverage and narrows the widths of confidence intervals produced by A-TMLE. We illustrate our method with a case study of augmenting the DEVOTE cardiovascular safety trial by using the Optum Clinformatics claims database.
From: Sky Qiu [view email]
[v1]
Wed, 29 Jan 2025 18:31:25 UTC (67 KB)
[v2]
Mon, 8 Jun 2026 22:54:16 UTC (52 KB)
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。